Neurosoft Bioelectronics announced it has closed a $7.5 million oversubscribed seed financing round to accelerate development of its stretchable and scalable brain-computer interface (BCI) platform. The funding will support the company’s minimally invasive neural interface technology, which has already been tested in 10 patients across clinical trials in the United States and Europe.
The financing round was led by Skybound Venture Capital, with participation from PL Capital, IAG Capital Partners, and Connecticut Innovations, among others. With the new capital, Neurosoft said its total funding raised to date now exceeds $20 million.
Neurosoft is developing a neural data platform designed to build a cortical foundation model using neural recordings collected from its implantable devices. The company said the model is intended to improve the performance of invasive BCIs for patients with severe neurological conditions while also supporting future non-invasive BCI applications.
The company’s proprietary soft and stretchable electrodes are designed to sit on the surface of the cortex without penetrating brain tissue. According to Neurosoft, the electrodes are up to 1,000 times more compliant than those used in other flexible neural interfaces, can cover up to 30 times more cortex than current state-of-the-art BCIs, and require only a minimally invasive procedure.
Neurosoft has conducted testing in 10 patients through two ongoing clinical trials at UTHealth Houston and UMC Utrecht. This includes what the company described as the first 64-channel soft and stretchable brain interface study for epilepsy surgery guidance.
The company said its technology portfolio includes more than 25 patents and more than 25 peer-reviewed publications. Neurosoft has also established a GMP manufacturing line in Switzerland, obtained ISO 13485 certification, and engaged with the FDA through multiple pre-submission meetings to support the regulatory pathway for its first commercial product.
Earlier this year, Neurosoft announced a partnership with Science Corp to help accelerate development of its BCI platform.
The newly raised funding will support near-term milestones including demonstrating minimally invasive deployment in human patients and pursuing commercialization of its first brain interface product in the United States.
KEY QUOTES:
“Our soft electrode platform, paired with a streamlined regulatory pathway, gives us access to neural data at a quality and scale no other approach can safely match today. That data is the foundation for improved clinical outcomes, and a cortical foundation model that will help shape the next generation of brain interfaces. The investor support we’ve seen in this round validates that we’re on the right path.”
Nicolas Vachicouras, PhD, CEO and Co-Founder, Neurosoft Bioelectronics
“Neurosoft isn’t just building a medical device; they are building the definitive interface between the human mind and the digital world. Their stretchable, sub-millimeter electrodes are a feat of engineering that finally allows us to interface seamlessly with the brain without damaging it. We are proud to lead this investment to accelerate their mission of treating devastating conditions like severe tinnitus and epilepsy, while simultaneously gathering the unprecedented neural data required to map and decode the human cortex at scale.”
George Varvarelis, GP, Skybound Venture Capital
